|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for DYRK2 |
 Gene summary |
| Basic gene Info. | Gene symbol | DYRK2 |
| Gene name | dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 | |
| Synonyms | - | |
| Cytomap | UCSC genome browser: 12q15 | |
| Type of gene | protein-coding | |
| RefGenes | NM_003583.3, NM_006482.2, | |
| Description | dual specificity tyrosine-phosphorylation-regulated kinase 2 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 603496 | |
| HGNC : HGNC | ||
| HPRD : 04606 | ||
| Protein | UniProt: Q92630 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_DYRK2 | |
| BioGPS: 8445 | ||
| Pathway | NCI Pathway Interaction Database: DYRK2 | |
| KEGG: DYRK2 | ||
| REACTOME: DYRK2 | ||
| Pathway Commons: DYRK2 | ||
| Context | iHOP: DYRK2 | |
| ligand binding site mutation search in PubMed: DYRK2 | ||
| UCL Cancer Institute: DYRK2 | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0006468 | protein phosphorylation | 11311121 | GO:0018108 | peptidyl-tyrosine phosphorylation | 9748265 | GO:0042771 | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 17349958 | GO:0045725 | positive regulation of glycogen biosynthetic process | 11311121 |
| Top |
| Ligand binding site mutations for DYRK2 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | F301 | M299I | SKCM | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for DYRK2 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | F301 | M299I | -0.83536995 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for DYRK2 from PDB |
| Top |
| Differential gene expression and gene-gene network for DYRK2 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for DYRK2 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0017661 | Glomerulonephritis, IGA | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for DYRK2 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of DYRK2 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
| Top |
| Conservation information for LBS of DYRK2 |
| Multiple alignments for Q92630 in multiple species |
| LBS | AA sequence | # species | Species | A249 | VHQHVALKMVR | 2 | Homo sapiens, Mus musculus | A249 | THEHVALKIVR | 1 | Drosophila melanogaster | A249 | YQQYVALKLVR | 1 | Caenorhabditis elegans | A249 | MHQHVALKMVR | 1 | Gallus gallus | D368 | GIKVIDFGSSC | 4 | Homo sapiens, Drosophila melanogaster, Caenorhabditis elegans, Gallus gallus | D368 | SIKVIDFGSSC | 1 | Mus musculus | E302 | ICMTFELLSMN | 3 | Homo sapiens, Mus musculus, Gallus gallus | E302 | TCITFELLSIN | 1 | Drosophila melanogaster | E302 | KCITFELLSIN | 1 | Caenorhabditis elegans | F233 | IGKGSFGQVVK | 3 | Homo sapiens, Mus musculus, Gallus gallus | F233 | IGKGSFGQVIK | 2 | Drosophila melanogaster, Caenorhabditis elegans | F301 | HICMTFELLSM | 3 | Homo sapiens, Mus musculus, Gallus gallus | F301 | HTCITFELLSI | 1 | Drosophila melanogaster | F301 | HKCITFELLSI | 1 | Caenorhabditis elegans | G229 | VLKVIGKGSFG | 4 | Homo sapiens, Caenorhabditis elegans, Mus musculus, Gallus gallus | G229 | MLKIIGKGSFG | 1 | Drosophila melanogaster | I228 | EVLKVIGKGSF | 4 | Homo sapiens, Caenorhabditis elegans, Mus musculus, Gallus gallus | I228 | EMLKIIGKGSF | 1 | Drosophila melanogaster | I367 | SGIKVIDFGSS | 4 | Homo sapiens, Drosophila melanogaster, Caenorhabditis elegans, Gallus gallus | I367 | SSIKVIDFGSS | 1 | Mus musculus | K251 | QHVALKMVRNE | 3 | Homo sapiens, Mus musculus, Gallus gallus | K251 | EHVALKIVRNE | 1 | Drosophila melanogaster | K251 | QYVALKLVRNE | 1 | Caenorhabditis elegans | L303 | CMTFELLSMNL | 3 | Homo sapiens, Mus musculus, Gallus gallus | L303 | CITFELLSINL | 2 | Drosophila melanogaster, Caenorhabditis elegans | L304 | MTFELLSMNLY | 3 | Homo sapiens, Mus musculus, Gallus gallus | L304 | ITFELLSINLY | 2 | Drosophila melanogaster, Caenorhabditis elegans | L355 | KPENILLKQQG | 3 | Homo sapiens, Mus musculus, Gallus gallus | L355 | KPENVLLKQQG | 2 | Drosophila melanogaster, Caenorhabditis elegans | S305 | TFELLSMNLYE | 3 | Homo sapiens, Mus musculus, Gallus gallus | S305 | TFELLSINLYE | 2 | Drosophila melanogaster, Caenorhabditis elegans | V236 | GSFGQVVKAYD | 3 | Homo sapiens, Mus musculus, Gallus gallus | V236 | GSFGQVIKAYD | 1 | Drosophila melanogaster | V236 | GSFGQVIKAFD | 1 | Caenorhabditis elegans |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |